DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Chi KN, Ellard S, Hotte SJ, Kollmannsberger C, Czaykwski P, Moore M, Winquist E, Ruether JD, Fisher B, Seymour L.
Phase II study of BAY 43 – 9006 (sorafenib) in patients with chemo-naive hormone refractory prostate cancer.
Eur J Can 2005; 3: 248-248
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.